← FDA DRUG APPROVALS

FDA ANDA · ANDA076345

GLYBURIDE AND METFORMIN HYDROCHLORIDE

Sponsor: IMPAX

APPLICATION
ANDA076345
TYPE
ANDA
ORIGINAL APPROVAL
2004-02-18
LATEST ACTION
2021-06-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

GLYBURIDE AND METFORMIN HYDROCHLORIDEPrescription
GLYBURIDE 5MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDEPrescription
GLYBURIDE 1.25MG, METFORMIN HYDROCHLORIDE 250MG · TABLET · ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDEPrescription
GLYBURIDE 2.5MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL

Approval history

2021-06-24Labeling · Supplement 36 · standardAP
2021-06-24Labeling · Supplement 34 · standardAP
2015-04-08Labeling · Supplement 32 · standardAP
2015-04-08Labeling · Supplement 19AP
2014-02-04Labeling · Supplement 26AP
2011-09-27Labeling · Supplement 30AP
2010-04-27Labeling · Supplement 29AP
2009-03-16Labeling · Supplement 23AP
2008-12-05Labeling · Supplement 22AP
2007-11-21Labeling · Supplement 13AP
2007-07-27Labeling · Supplement 16AP
2006-03-02Labeling · Supplement 7AP
2005-07-26Labeling · Supplement 5AP
2004-02-18OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →